Abstract | OBJECTIVE: METHODS: We queried the TriNetX network database, a global health research network consisting of 65 million men in 44 large healthcare organizations, to investigate rates of PSA testing in 4 cohorts of men aged 55-69 with a history of PCa diagnosis and/or a prescription for any route or formulation of testosterone. We further stratified each cohort to evaluate PSA testing in men with previously treated ( CPT 55,840, 55,866, 77,778, 77,385) or untreated PCa. All cohorts' PSA testing rates were compared against the "no PCa or TT" cohort by Chi-square test. RESULTS: A total of 4,525,259 men, aged 55-69, were included in our study. Following stratification into cohorts based on PCa or TT history, we found that 14.2% (P < .0001) of men without PCa or TT underwent PSA testing following an initial ambulatory visit. Among men without PCa who received TT, 33.6% (P < .0001) underwent testing. Unfortunately, only 53.2% (P < .0001) and 61.0% (P < .0001) of men receiving TT with previously untreated and treated PCa, respectively, had PSA testing. CONCLUSION: In contrast to current guidelines, a large proportion of men receiving TT and with a history of PCa did not undergo PSA testing. Further studies are necessary to better characterize reasons why PSA testing rates are low even in this high-risk cohort.
|
Authors | Matthew M Mason, Sirpi Nackeeran, Soum D Lokeshwar, Ruben Blachman-Braun, Ranjith Ramasamy |
Journal | Urology
(Urology)
Vol. 165
Pg. 237-241
(07 2022)
ISSN: 1527-9995 [Electronic] United States |
PMID | 35227710
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Copyright | Published by Elsevier Inc. |
Chemical References |
- Testosterone
- Prostate-Specific Antigen
|
Topics |
- Biopsy
- Humans
- Male
- Prostate-Specific Antigen
- Prostatectomy
- Prostatic Neoplasms
(diagnosis, drug therapy, surgery)
- Testosterone
(therapeutic use)
|